Orchestra BioMed (OBIO) Stock Forecast & Price Target $5.53 +0.06 (+1.10%) As of 09:55 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Orchestra BioMed - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 7 Analyst RatingsSell1Hold0Buy6 Based on 7 Wall Street analysts who have issued ratings for Orchestra BioMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a sell rating, and 6 have given a buy rating for OBIO. Consensus Price Target $13.17138.10% Upside According to the 7 analysts' twelve-month price targets for Orchestra BioMed, the average price target is $13.17. The highest price target for OBIO is $20.00, while the lowest price target for OBIO is $10.00. The average price target represents a forecasted upside of 138.10% from the current price of $5.53. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for OBIO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Orchestra BioMed and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OBIO Analyst Ratings Over TimeTypeCurrent Forecast10/23/25 to 10/23/261 Month Ago9/23/25 to 9/23/263 Months Ago7/25/25 to 7/25/261 Year Ago10/23/24 to 10/23/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)Buy6 Buy rating(s)6 Buy rating(s)5 Buy rating(s)3 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)1 Hold rating(s)1 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$13.17$13.17$13.60$13.50Forecasted Upside138.10% Upside122.03% Upside263.64% Upside255.26% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy OBIO Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History OBIO Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Orchestra BioMed Stock vs. The CompetitionTypeOrchestra BioMedHealthcare CompaniesBroader MarketConsensus Rating Score 2.71 2.32 2.53Consensus RatingModerate BuyHoldModerate BuyPredicted Upside140.71% Upside1,334.40% Upside15.80% UpsideNews Sentiment RatingNeutral NewsSee Recent OBIO NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/23/2024 - 10/23/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/23/2026 Chardan Capital5 of 5 starsKeay Nakae4 of 5 starsReiterated RatingBuy$20.00+265.63%10/15/2026 Piper Sandler2 of 5 starsMatt O'Brien2 of 5 starsReiterated RatingOverweight10/5/2026 HC Wainwright4 of 5 starsYi Chen2 of 5 starsReiterated RatingBuy$10.00+68.07%9/15/2026 B. Riley FinancialSubscribe to MarketBeat All Access to unlock brokerage rankingsMadison El-SaadiSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$10.00 ➝ $11.00+83.00%9/10/2026 Weiss RatingsSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeSell (E+) ➝ Sell (D-)5/13/2026 BarclaysSubscribe to MarketBeat All Access to unlock brokerage rankingsMatt MiksicSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$12.00 ➝ $13.00+220.20%12/10/2025 TD CowenSubscribe to MarketBeat All Access to unlock brokerage rankings Initiated CoverageBuy8/20/2025 BTIG ResearchSubscribe to MarketBeat All Access to unlock brokerage rankingsMarie ThibaultSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy ➝ NeutralAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:56 AM ET. OBIO Forecast - Frequently Asked Questions What is Orchestra BioMed's forecast for 2026? According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Orchestra BioMed is $13.17, with a high forecast of $20.00 and a low forecast of $10.00. Should I buy or sell Orchestra BioMed stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Orchestra BioMed in the last year. There is currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OBIO shares. Does Orchestra BioMed's stock price have much upside? According to analysts, Orchestra BioMed's stock has a predicted upside of 138.10% based on their 12-month stock forecasts. Has Orchestra BioMed been upgraded by Wall Street analysts recently? Over the previous 90 days, Orchestra BioMed's stock had 1 upgrade by analysts. What analysts cover Orchestra BioMed? Orchestra BioMed has been rated by research analysts at B. Riley Financial, Chardan Capital, HC Wainwright, Piper Sandler, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Orchestra BioMed more than its competitors? Analysts like Orchestra BioMed more than other "healthcare" companies. The consensus rating for Orchestra BioMed is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how OBIO compares to other companies. Stock Forecasts and Research Tools Related Companies CONMED Stock Forecast Alpha Tau Medical Stock Forecast iRadimed Stock Forecast Bioventus Stock Forecast Tandem Diabetes Care Stock Forecast STAAR Surgical Stock Forecast Enovis Stock Forecast Artivion Stock Forecast Integra LifeSciences Stock Forecast PROCEPT BioRobotics Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Orchestra BioMed RecommendationsPiper SandlerHC WainwrightB. Riley FinancialWeiss RatingsWall Street ZenBarclaysChardan CapitalTD Cowen MarketBeat monitors more than a dozen sources for Orchestra BioMed analyst ratings, with the most recent rating issued on 10/23/2026. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orchestra BioMed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
